Anti-PD-1 antibody, antigen-binding fragment thereof and pharmaceutical use thereof
US12428482B2 · kind B2 · utility
0Cited by
3References
19Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Jan 31, 2020 |
| Grant date | Sep 30, 2025 |
| Priority date | — |
| Expiry date | Jan 29, 2043 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N15/11
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Provided are an anti-PD-1 antibody, an antigen-binding fragment thereof, and a pharmaceutical use thereof. Specifically, provided are a humanized anti-PD-1 antibody containing a specific CDR region and an antigen-binding fragment thereof, a pharmaceutical composition containing the anti-PD-1 antibody and the antigen-binding fragment thereof, and a used thereof as medicament. In particular, provided is a use of the humanized anti-PD-1 antibody in the preparation of the medicament for treating PD-1 associated diseases or disorders.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.